Nilsine Partners LLC Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

Nilsine Partners LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 31.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,960 shares of the biopharmaceutical company’s stock after selling 5,368 shares during the period. Nilsine Partners LLC’s holdings in Pfizer were worth $317,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. AQR Capital Management LLC increased its holdings in shares of Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after acquiring an additional 9,435 shares in the last quarter. Quarry LP purchased a new position in Pfizer in the second quarter worth about $31,000. Dana Investment Advisors Inc. raised its holdings in Pfizer by 9.6% in the 2nd quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock worth $2,803,000 after acquiring an additional 8,771 shares during the last quarter. Souders Financial Advisors lifted its position in Pfizer by 6.1% in the 2nd quarter. Souders Financial Advisors now owns 8,347 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 483 shares in the last quarter. Finally, Birmingham Capital Management Co. Inc. AL boosted its stake in Pfizer by 0.9% during the 2nd quarter. Birmingham Capital Management Co. Inc. AL now owns 181,763 shares of the biopharmaceutical company’s stock valued at $5,086,000 after purchasing an additional 1,559 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.65 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50-day simple moving average of $26.18 and a two-hundred day simple moving average of $27.91. The firm has a market capitalization of $151.00 billion, a PE ratio of 36.01, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. Analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Finally, Guggenheim dropped their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.